Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

BACKGROUND: In a phase III trial in patients with castration-resistant prostate cancer (CRPC) and bone metastases, denosumab was superior to zoledronic acid in reducing skeletal-related events (SREs; radiation to bone, pathologic fracture, surgery to bone, or spinal cord compression). This study rea...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Smith, M. R., Coleman, R. E., Klotz, L., Pittman, K., Milecki, P., Ng, S., Chi, K. N., Balakumaran, A., Wei, R., Wang, H., Braun, A., Fizazi, K.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2015
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4304378/
https://ncbi.nlm.nih.gov/pubmed/25425475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu519
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki